Recombinant Anti-Map17 antibody [EPR10372] (ab156014)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR10372] to Map17
- Suitable for: WB, IHC-P
- Reacts with: Human
Overview
-
Product name
Anti-Map17 antibody [EPR10372]
See all Map17 primary antibodies -
Description
Rabbit monoclonal [EPR10372] to Map17 -
Host species
Rabbit -
Tested applications
Suitable for: WB, IHC-Pmore details
Unsuitable for: ICC or IP -
Species reactivity
Reacts with: Human -
Immunogen
Recombinant fragment corresponding to Human Map17.
-
Positive control
- Human fetal kidney lysate; Human breast carcinoma and lung carcinoma tissues.
-
General notes
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at -20ºC. -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, 50% Tissue culture supernatant -
Concentration information loading...
-
Purity
Tissue culture supernatant -
Clonality
Monoclonal -
Clone number
EPR10372 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
Applications
Our Abpromise guarantee covers the use of ab156014 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB | 1/1000 - 1/10000. Predicted molecular weight: 12 kDa. | |
IHC-P | 1/100 - 1/250. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
Target
-
Relevance
MAP17 is a 17 kDa membrane-associated protein expressed abundantly in carcinomas arising from kidney, colon, lung, and breast. In normal tissues it is expressed in significant amounts in the kidney. -
Cellular localization
Plasma membrane -
Database links
- Entrez Gene: 10158 Human
- Omim: 607178 Human
- SwissProt: Q13113 Human
-
Alternative names
- 17 kDa membrane associated protein antibody
- DD96 antibody
- Epithelial protein up regulated in carcinoma membrane associated protein 17 antibody
see all
Images
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Map17 antibody [EPR10372] (ab156014)
ab156014 showing +ve staining in Human urinary bladder transitional carcinoma.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Map17 antibody [EPR10372] (ab156014)
ab156014 showing +ve staining in Human ovarian carcinoma.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Map17 antibody [EPR10372] (ab156014)
ab156014 showing +ve staining in Human colonic adenocarcinoma.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Map17 antibody [EPR10372] (ab156014)
ab156014 showing +ve staining in Human cervical carcinoma.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
-
Anti-Map17 antibody [EPR10372] (ab156014) at 1/1000 dilution + Human fetal kidney lysate at 10 µg
Secondary
HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 12 kDa -
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Map17 antibody [EPR10372] (ab156014)
Immunohistochemical analysis of paraffin-embedded Human breast carcinoma tissue labeling Map17 with ab156014 at 1/100 dilution.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Map17 antibody [EPR10372] (ab156014)
Immunohistochemical analysis of paraffin-embedded Human lung carcinoma tissue labeling Map17 with ab156014 at 1/100 dilution.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
Protocols
Datasheets and documents
References (2)
ab156014 has been referenced in 2 publications.
- Tampaki EC et al. Combined Fascin-1 and MAP17 Expression in Breast Cancer Identifies Patients with High Risk for Disease Recurrence. Mol Diagn Ther 23:635-644 (2019). PubMed: 31273628
- Chen X et al. Elevation of MAP17 enhances the malignant behavior of cells via the Akt/mTOR pathway in hepatocellular carcinoma. Oncotarget 8:92589-92603 (2017). PubMed: 29190940